CRANBURY, N.J.– Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Jessie Yeung as Vice President of Investor Relations and Corporate Finance. Ms. Yeung brings more than 15 years of investor relations, corporate finance and capital market experience across industries including the biopharmaceutical and financial sectors. She will be responsible for leading the investor relations function and capital markets strategy.
“I’m thrilled to welcome Jessie to Rocket as we continue to advance our world-class pipeline of gene therapy clinical programs and move toward multiple key milestones as a Company, including our first top-line readouts this year,” said Gaurav Shah, Chief Executive Officer of Rocket Pharma. “Jessie’s breadth of relationships and experience with the investor community and wealth of finance expertise will be invaluable for our investors, existing and new, as we continue our growth trajectory. Jessie’s leadership will be instrumental in communicating Rocket’s unique approach to gene therapy and progress in our relentless pursuit of innovative gene therapy cures for rare and devastating diseases.”
Prior to joining Rocket, Ms. Yeung was the Head of Corporate Finance and Investor Relations at Legend Biotech. There, she developed the company’s comprehensive investor relations strategy leading to exceptional investor relationships, while also helping raise over $1 billion through private placements and public offerings as well as launching the largest biotech IPO of 2020. Prior to Legend Biotech, she covered the large-cap biotechnology sector as an equity research analyst at Bank of America Merrill Lynch, as well as the pharmaceuticals sector at Wells Fargo and consumer retail sector while at J.P. Morgan. During her tenure in equity research, Ms. Yeung developed an extensive network of investors. Earlier in her career, Ms. Yeung was with J.P. Morgan for over 10 years, where she held corporate finance roles including financial planning and analysis, product and valuation control, business development and risk management.
“It’s a tremendous honor to join the passionate and talented team at Rocket, given its unique and exciting pipeline of multi-platform clinical programs and leadership in the fast-growing field of gene therapy,” said Ms. Yeung. “I’m excited to continue to engage with the investment community to tell Rocket’s story and create long-term value for shareholders.”
Ms. Yeung earned her bachelor’s degree in Business Administration from Carnegie Mellon University and MBA from Columbia Business School.
